FAREED A ARIF

Allopathic & Osteopathic Physicians|Internal Medicine|Nephrology KENNEWICK, WA NPI 1073616611

General Payments — all program years on this page

$1,895.15

  • Category: General Payments
  • Program years: PY2018–2024
  • Record count: 40
  • As of (CMS publication): 2026-01-23

Latest program year (PY2024): $475.36 across 14 records · disputed records: 0

Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.

How this figure is calculated
  • The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
  • Methodology & Data — sourcing, labeling, and limitations.

By nature of payment

Latest program year (PY2024) · sorted by reported total.

Nature of paymentAmountRecords
Food and Beverage $453.807
Education $21.567

By paying entity

Latest program year (PY2024) · sorted by reported total.

Paying entityAmountRecords
Retrophin, Inc. $289.9810
Ardelyx, Inc. $126.301
Otsuka America Pharmaceutical, Inc. $25.481
NOVARTIS PHARMACEUTICALS CORPORATION $17.501
Novo Nordisk AS $16.101

By program year

Program yearAmountRecords
2018 $37.263
2019 $279.933
2020 $11.091
2021 $241.727
2022 $247.545
2023 $602.257
2024 $475.3614

Records — PY2024 (14)

Record IDPaying entityAmountDate Nature of paymentDispute statusPublishedSource
1086782095 Novartis Pharmaceuticals Corporation $17.50 11/12/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1097782542 Novo Nordisk Inc $16.10 06/04/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1118854794 Otsuka America Pharmaceutical, Inc. $25.48 09/11/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1146669336 Ardelyx, Inc. $126.30 05/08/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1149938795 Travere Therapeutics, Inc. $3.08 03/26/2024 Education Undisputed 01/23/2026 View at CMS
1149938799 Travere Therapeutics, Inc. $3.08 03/26/2024 Education Undisputed 01/23/2026 View at CMS
1149938803 Travere Therapeutics, Inc. $3.08 03/26/2024 Education Undisputed 01/23/2026 View at CMS
1149938807 Travere Therapeutics, Inc. $3.08 03/26/2024 Education Undisputed 01/23/2026 View at CMS
1149938811 Travere Therapeutics, Inc. $3.08 03/26/2024 Education Undisputed 01/23/2026 View at CMS
1149938815 Travere Therapeutics, Inc. $3.08 03/26/2024 Education Undisputed 01/23/2026 View at CMS
1149938819 Travere Therapeutics, Inc. $3.08 03/26/2024 Education Undisputed 01/23/2026 View at CMS
1149938823 Travere Therapeutics, Inc. $21.37 10/07/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1149938827 Travere Therapeutics, Inc. $105.69 06/20/2024 Food and Beverage Undisputed 01/23/2026 View at CMS
1149938831 Travere Therapeutics, Inc. $141.36 01/15/2024 Food and Beverage Undisputed 01/23/2026 View at CMS

Provenance & corrections

  • Dataset: CMS Open Payments — General Payments
  • Source: CMS Open Payments dataset (bulk file)
  • Publisher of source data: Centers for Medicare & Medicaid Services
  • Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.